Budget Impact Analysis
Annual Medical Discovery Budget
This table shows how Protocol + can reallocate administrative overhead (65% reduction) to high‑value research and validation activities, improving both efficiency and scientific output without increasing total budget.
| Category | Description | Share of Budget | Amount (USD) | With Protocol+ Impact |
|---|---|---|---|---|
| Preclinical experiments | Bench, in vivo, in vitro, assay development, exploratory work. | 40% | $40M | $40M (capacity increases via fewer repeats) |
| Clinical / validation studies | Pilot clinical studies, diagnostic validation, biomarker replication. | 30% | $30M | $30M (higher-quality inputs, fewer failed studies) |
| Administrative & compliance | Protocol drafting, IRB / ethics forms, monitoring logs, reporting, data entry. | 20% | $20M |
$7M residual $13M freed (65% reduction) |
| General overhead | Facilities, utilities, core IT not directly tied to studies. | 10% | $10M | $10M (unchanged) |
| Total Annual Budget | Complete medical discovery program | 100% | $100M |
$100M total $13M/year shifted from low‑value admin to experiments, validation, or headcount |
Key Insight: Protocol + doesn’t increase total spending—it reallocates administrative overhead
to high‑value research activities, translating unused capacity and reduced rework into measurable scientific output
and faster validation timelines.